Literature DB >> 18214426

Use of recombinant human activated protein C in patients with severe sepsis: a French retrospective multicentre study.

Laurent Muller, Samir Jaber, Alice Raillard, Jean Yves Lefrant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18214426     DOI： 10.1007/s00134-008-0997-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  7 in total

1.  Prescription of rh-APC differs substantially among western European countries.

Authors:  Marcus J Schultz; Marcel Levi
Journal:  Intensive Care Med       Date:  2006-03-07       Impact factor: 17.440

2.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

3.  Early changes in organ function predict eventual survival in severe sepsis.

Authors:  Mitchell M Levy; William L Macias; Jean-Louis Vincent; James A Russell; Eliezer Silva; Benjamin Trzaskoma; Mark D Williams
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

4.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Authors:  Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

5.  Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

Authors:  Salmaan Kanji; Marc M Perreault; Clarence Chant; David Williamson; Lisa Burry
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440

Review 6.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.

Authors:  R C Bone; R A Balk; F B Cerra; R P Dellinger; A M Fein; W A Knaus; R M Schein; W J Sibbald
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

7.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2007-12-04       Impact factor: 17.440
  7 in total
  1 in total

1.  Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

Authors:  Simon Finfer; V Marco Ranieri; B Taylor Thompson; Philip S Barie; Jean-François Dhainaut; Ivor S Douglas; Bengt Gårdlund; John C Marshall; Andrew Rhodes
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.